Park Place Capital Corp Sells 1,490 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Park Place Capital Corp reduced its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 17.7% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 6,941 shares of the biopharmaceutical company’s stock after selling 1,490 shares during the period. Park Place Capital Corp’s holdings in Gilead Sciences were worth $641,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in GILD. nVerses Capital LLC purchased a new position in Gilead Sciences during the 3rd quarter valued at about $25,000. Valued Wealth Advisors LLC grew its holdings in shares of Gilead Sciences by 101.9% during the third quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 161 shares in the last quarter. Decker Retirement Planning Inc. purchased a new position in shares of Gilead Sciences during the fourth quarter worth about $29,000. Strategic Investment Solutions Inc. IL purchased a new position in shares of Gilead Sciences during the second quarter worth about $33,000. Finally, Quarry LP purchased a new position in shares of Gilead Sciences during the second quarter worth about $43,000. 83.67% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research analysts have recently commented on the company. Daiwa America raised Gilead Sciences to a “hold” rating in a report on Monday, November 18th. Needham & Company LLC reaffirmed a “hold” rating on shares of Gilead Sciences in a research note on Thursday, November 7th. Maxim Group lowered Gilead Sciences from a “buy” rating to a “hold” rating in a research note on Friday, November 8th. Truist Financial upped their target price on Gilead Sciences from $83.00 to $97.00 and gave the stock a “hold” rating in a research note on Friday, November 8th. Finally, Robert W. Baird upped their target price on Gilead Sciences from $80.00 to $95.00 and gave the stock a “neutral” rating in a research note on Thursday, November 7th. Eleven analysts have rated the stock with a hold rating, thirteen have given a buy rating and four have given a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $97.96.

Insider Transactions at Gilead Sciences

In related news, insider Merdad Parsey sold 25,590 shares of the company’s stock in a transaction dated Wednesday, November 6th. The stock was sold at an average price of $91.50, for a total value of $2,341,485.00. Following the completion of the transaction, the insider now owns 99,599 shares of the company’s stock, valued at approximately $9,113,308.50. This represents a 20.44 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Andrew D. Dickinson sold 2,500 shares of the company’s stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $91.35, for a total value of $228,375.00. Following the completion of the transaction, the chief financial officer now directly owns 129,873 shares of the company’s stock, valued at $11,863,898.55. The trade was a 1.89 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 456,234 shares of company stock worth $42,130,461 over the last quarter. 0.29% of the stock is currently owned by insiders.

Gilead Sciences Stock Down 0.6 %

Gilead Sciences stock opened at $92.37 on Wednesday. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.10 and a current ratio of 1.26. The business’s 50-day simple moving average is $91.62 and its two-hundred day simple moving average is $84.57. The company has a market cap of $115.12 billion, a PE ratio of 1,025.86, a PEG ratio of 1.29 and a beta of 0.18. Gilead Sciences, Inc. has a fifty-two week low of $62.07 and a fifty-two week high of $98.90.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, beating the consensus estimate of $1.58 by $0.44. The business had revenue of $7.55 billion for the quarter, compared to the consensus estimate of $7.01 billion. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The company’s quarterly revenue was up 7.0% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.29 EPS. Equities analysts anticipate that Gilead Sciences, Inc. will post 4.36 EPS for the current year.

Gilead Sciences Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Monday, December 30th. Shareholders of record on Friday, December 13th were paid a dividend of $0.77 per share. The ex-dividend date was Friday, December 13th. This represents a $3.08 annualized dividend and a yield of 3.33%. Gilead Sciences’s payout ratio is presently 3,422.22%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.